Literature DB >> 20823080

Lamotrigine: when and where does it act in affective disorders? A systematic review.

Benedikt Amann1, Christoph Born, Jose Manuel Crespo, Edith Pomarol-Clotet, Peter McKenna.   

Abstract

Recent published data and treatment guidelines have created uncertainty about the use of lamotrigine in affective disorders, especially in acute bipolar depression. Furthermore, unpublished data on lamotrigine in mania, mixed episodes, unipolar depression and rapid cycling are still waiting to be integrated into the literature. Therefore, we critically reviewed the position of lamotrigine in the acute and long-term treatment of affective disorders. Studies were identified by searching English language articles published in MEDLINE using the key words: lamotrigine, bipolar depression, unipolar depression, mania, mixed episode, long-term treatment, rapid-cycling. Results of unpublished trials were obtained from the GlaxoSmithKline website. Lamotrigine showed efficacy in the prophylaxis of bipolar disorder, more so in depressive than manic episodes. There was no evidence of effectiveness in the acute treatment of mania, mixed episodes, unipolar depression or rapid-cycling bipolar I disorder. Its effect in the acute treatment of bipolar depression is at most small. Based on current evidence, lamotrigine is indicated for the prophylaxis of bipolar disorder with predominantly depressive episodes. Its effectiveness in the acute treatment of bipolar depression is open to debate, and practical considerations limit its usefulness here. There are no grounds for recommending its use in manic or mixed states, in rapidly-cycling bipolar I or in unipolar depression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20823080     DOI: 10.1177/0269881110376695

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  12 in total

Review 1.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

2.  Effect of lamotrigine and carbamazepine on corticotropin-releasing factor-associated serotonergic transmission in rat dorsal raphe nucleus.

Authors:  Shunske Tanahashi; Satoshi Yamamura; Masanori Nakagawa; Eishi Motomura; Motohiro Okada
Journal:  Psychopharmacology (Berl)       Date:  2011-09-27       Impact factor: 4.530

Review 3.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

Review 4.  Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans.

Authors:  Mireille Basselin; Epolia Ramadan; Stanley I Rapoport
Journal:  Brain Res Bull       Date:  2011-12-09       Impact factor: 4.077

5.  Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder at Any Phase of Illness and at least Mild Symptom Severity.

Authors:  Keming Gao; Jodi G Arnold; Thomas J Prihoda; Marlon Quinones; Vivek Singh; Martha Schinagle; Carla Conroy; Nicole D'Arcangelo; Yuanhan Bai; Joseph R Calabrese; Charles L Bowden
Journal:  Psychopharmacol Bull       Date:  2020-05-19

6.  A pilot open series of lamotrigine in DBT-treated eating disorders characterized by significant affective dysregulation and poor impulse control.

Authors:  Mary Ellen Trunko; Terry A Schwartz; Laura A Berner; Anne Cusack; Tiffany Nakamura; Ursula F Bailer; Joanna Y Chen; Walter H Kaye
Journal:  Borderline Personal Disord Emot Dysregul       Date:  2017-10-08

7.  Informing DSM-5: biological boundaries between bipolar I disorder, schizoaffective disorder, and schizophrenia.

Authors:  Victoria E Cosgrove; Trisha Suppes
Journal:  BMC Med       Date:  2013-05-14       Impact factor: 8.775

8.  A critical review of the recent literature and selected therapy guidelines since 2006 on the use of lamotrigine in bipolar disorder.

Authors:  Anja Tränkner; Christian Sander; Peter Schönknecht
Journal:  Neuropsychiatr Dis Treat       Date:  2013-01-18       Impact factor: 2.570

Review 9.  Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer.

Authors:  Kedar S Prabhavalkar; Nimmy B Poovanpallil; Lokesh K Bhatt
Journal:  Front Pharmacol       Date:  2015-10-23       Impact factor: 5.810

Review 10.  Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants.

Authors:  Roger A Kroes; Carol L Nilsson
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.